Comprehensive Investigation of Natural Ligands as Inhibitors of β Secretase to Identify Alzheimer's Disease Therapeutics

被引:0
作者
Kushwah, Shikha [1 ]
Mani, Ashutosh [1 ]
机构
[1] Motilal Nehru Natl Inst Technol Allahabad, Dept Biotechnol, Prayagraj 211004, India
关键词
Alzheimer's disease; BACE1; amyloid-beta hypothesis; molecular docking; MD (molecular dynamics) simulation; herbal compounds; AMYLOID HYPOTHESIS; BACE1; PATHOGENESIS; PREDICTIONS; CURCUMIN; DOCKING;
D O I
10.2174/0115672050323622240705043337
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Alzheimer's disease (AD) is an alarmingly prevalent worldwide neurological disorder that affects millions of people and has severe effects on cognitive functions. The amyloid hypothesis, which links AD to A beta (amyloid beta) plaque aggregation, is a well-acknowledged theory. The beta-secretase (BACE1) is the main cause of A beta production, which makes it a possible target for therapy. FDA-approved therapies for AD do exist, but none of them explicitly target BACE1, and their effectiveness is constrained and accompanied by adverse effects.Materials and Methods We determined the essential chemical components of medicinal herbs by conducting a thorough literature research for BACE1. Computational methods like molecular docking, ADMET (Absorption, distribution, metabolism, excretion, toxicity) screening, molecular dynamic simulations, and MMPBSA analysis were performed in order to identify the most promising ligands for beta-secretase.Results The results suggested that withasomniferol, tinosporide, and curcumin had better binding affinity with BACE1, suggesting their potential as therapeutic candidates against Alzheimer's disease.Conclusion Herbal therapeutics have immense applications in the treatment of chronic diseases like Alzheimer's disease, and there is an urgent need to assess their efficacy as therapeutics.
引用
收藏
页码:667 / 678
页数:12
相关论文
共 50 条
  • [1] Engineered heparins:: Novel β-secretase inhibitors as potential Alzheimer's disease therapeutics
    Patey, S. J.
    Edwards, E. A.
    Yates, E. A.
    Turnbull, J. E.
    NEURODEGENERATIVE DISEASES, 2008, 5 (3-4) : 197 - 199
  • [2] γ-Secretase inhibitors and Alzheimer's disease
    Roberts, SB
    ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (12) : 1579 - 1588
  • [3] γ-Secretase Inhibitors for the Treatment of Alzheimer's Disease
    Wu, Wen-Lian
    Zhang, Lili
    DRUG DEVELOPMENT RESEARCH, 2009, 70 (02) : 94 - 100
  • [4] -secretase inhibitors for Alzheimer's disease: identification using pharmacoinformatics
    Islam, Md Ataul
    Pillay, Tahir S.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2019, 37 (02) : 503 - 522
  • [5] Prospects of -Secretase Inhibitors for the Treatment of Alzheimer's Disease
    Ghosh, Arun K.
    Tang, Jordan
    CHEMMEDCHEM, 2015, 10 (09) : 1463 - 1466
  • [7] Developing ß-secretase inhibitors for treatment of Alzheimer's disease
    Ghosh, Arun K.
    Brindisi, Margherita
    Tang, Jordan
    JOURNAL OF NEUROCHEMISTRY, 2012, 120 : 71 - 83
  • [8] Screening natural inhibitors against upregulated G-protein coupled receptors as potential therapeutics of Alzheimer's disease
    Chaudhary, Amit
    Singh, Vishal
    Varadwaj, Pritish Kumar
    Mani, Ashutosh
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (02) : 673 - 684
  • [9] Computer-Aided Drug Design of β-Secretase, γ-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer's Therapeutics
    Mouchlis, Varnavas D.
    Melagraki, Georgia
    Zacharia, Lefteris C.
    Afantitis, Antreas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (03)
  • [10] A microfluidics-based mobility shift assay to identify new inhibitors of β-secretase for Alzheimer’s disease
    Rongfeng Liu
    Yu-Chih Liu
    Junwei Meng
    Haiyan Zhu
    Xuehong Zhang
    Analytical and Bioanalytical Chemistry, 2017, 409 : 6635 - 6642